Circassia Pharmaceuticals Plc Director/PDMR Shareholding (2443Q)

TIDMCIR

RNS Number : 2443Q

Circassia Pharmaceuticals Plc

04 June 2018

Persons Discharging Managerial Responsibilities / persons closely associated with them (PDMR) Notification

4 June 2018: Circassia Pharmaceuticals plc (LSE: CIR).

1 - Details of the person discharging managerial responsibilities/person closely associated

 
 Name   Rod Hafner 
-----  ----------- 
 

2 - Reason for the notification

 
 Position/status                   Director and Senior Vice 
                                    President Research & 
                                    Development (PDMR) 
--------------------------------  ------------------------- 
 Initial notification/amendment*   Initial Notification 
--------------------------------  ------------------------- 
 In case of amendment,             N/A 
  please enter the previous 
  notification reference 
  number and explain the 
  error that this notification 
  needs amending 
--------------------------------  ------------------------- 
 

3 - Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 
 Full name of entity*      Circassia Pharmaceuticals 
                            plc 
------------------------  -------------------------- 
 Legal Entity Identifier   2138006YAT138TOGA556 
  code 
------------------------  -------------------------- 
                           In accordance with ISO 
                            1744 LEI code 
------------------------  -------------------------- 
 

4 - Details of the transaction(s)

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted

 
   Date          Description of       Aggregated   Aggregated      Total 
              Financial Transaction      Price       Volume      Aggregated 
                                                                   Price 
----------  -----------------------  -----------  -----------  ------------ 
 31-May-18   Grant of options         GBP0.0008     250,000       GBP200 
              under the 2018 
              Share Option 
              scheme. 
----------  -----------------------  -----------  -----------  ------------ 
 
   i.          Award of options 
 
 Description of the financial      Circassia Pharmaceuticals 
  instrument, type of instrument    Plc 2018 Performance 
                                    Share Plan 
--------------------------------  -------------------------------- 
 Identification Code               N/A 
--------------------------------  -------------------------------- 
 Nature of the transaction         Award of options 
--------------------------------  -------------------------------- 
 Currency                          GBP 
--------------------------------  -------------------------------- 
 Price(s) and Volume (s)              Price      Volume    Total 
                                    -----------  --------  ------- 
                                     GBP0.0008p   250,000   GBP200 
                                    -----------  --------  ------- 
--------------------------------  -------------------------------- 
 Aggregated Information               Price      Volume    Total 
                                    -----------  --------  ------- 
                                     GBP0.0008p   250,000   GBP200 
                                    -----------  --------  ------- 
--------------------------------  -------------------------------- 
 Date of Transaction               31 May 2018 
--------------------------------  -------------------------------- 
 Place of Transaction              London: XLON 
--------------------------------  -------------------------------- 
 
 
 For further information, please contact: 
 Circassia Pharmaceuticals plc 
  Julien Cotta, Company Secretary      [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHBUGDLSBGBGIS

(END) Dow Jones Newswires

June 04, 2018 11:15 ET (15:15 GMT)